CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
Cash Flows from Operating Activities
Net (loss) income	$ (3,147)	$ 8,256
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Amortization	1,020	1,163
Depreciation	874	895
(Income) loss from investments in equity securities, net	(274)	991
Charge for the acquisition of Prometheus Biosciences, Inc.	10,217	0
Charge for the acquisition of Imago BioSciences, Inc.	1,192	0
Deferred income taxes	(632)	(600)
Share-based compensation	314	257
Other	5	799
Net changes in assets and liabilities	(4,526)	(2,698)
Net Cash Provided by Operating Activities	5,043	9,063
Cash Flows from Investing Activities
Capital expenditures	(1,972)	(2,113)
Purchases of securities and other investments	(587)	(705)
Proceeds from sales of securities and other investments	785	374
Acquisition of Prometheus Biosciences, Inc., net of cash acquired	(10,705)	0
Acquisition of Imago BioSciences, Inc., net of cash acquired	(1,327)	0
Other	4	194
Net Cash Used in Investing Activities	(13,802)	(2,250)
Cash Flows from Financing Activities
Net change in short-term borrowings	1,937	0
Proceeds from issuance of debt	5,946	0
Payments on debt	(1,751)	(1,250)
Purchases of treasury stock	(487)	0
Dividends paid to stockholders	(3,738)	(3,515)
Proceeds from exercise of stock options	112	109
Other	(315)	(207)
Net Cash Provided by (Used in) Financing Activities	1,704	(4,863)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	(6)	(364)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	(7,061)	1,586
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $79 and $71 at January 1, 2023 and 2022, respectively, included in Other current assets)	12,773	8,167
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $52 and $78 at June 30, 2023 and 2022, respectively, included in Other current assets)	$ 5,712	$ 9,753